J&J’s Planned New Consumer Health Company Named Kenvue

Modern name, purpose, and visual identity mark inspiring next chapter for maker of iconic, trusted brands, including Tylenol, Neutrogena, Listerine, and Band-Aid Brand

On Sep 29, 2022

New Brunswick-based Johnson & Johnson (J&J) took another step forward yesterday in establishing two independent, market-leading companies with the announcement of Kenvue as the name for the planned New Consumer Health Company.

According to the company, “Kenvue (pronounced ken·view), is inspired by two powerful ideas: “ken” – meaning knowledge, an English word primarily used in Scotland, and “vue,” referencing sight. With rich knowledge of human needs and deep consumer insights, Kenvue will deliver meaningful, personal health solutions.”

“Unveiling the Kenvue brand is a defining moment for our stakeholders and an important part of the planned separation,” said Thibaut Mongon, CEO designate, Kenvue. “We breathe life into some of the world’s most iconic and beloved brands every day, so we harnessed that same expertise, love, and energy into developing our new corporate identity.”

Kenvue’s purpose, Realize the Extraordinary Power of Everyday Care, will guide the company’s actions and long-term aspirations, from strategy to talent philosophy, and more, according to J&J.

“We believe that daily self-care rituals add up over time and have a profound cumulative impact on your wellbeing. This is the extraordinary power of everyday care. And our work is to put that power into the hands of consumers around the world,” Mongon adds.

Joaquin Duato, chief executive officer of J&J adds, “The announcement is another milestone for the Consumer Health business. Kenvue is poised to thrive as a standalone company with a leading portfolio of brands consumers love and trust. I’m confident in this team and excited to see what the future holds.”

Kenvue will become a standalone leading global consumer health company in 2023, subject to legal requirements including consultation with works councils and employee representatives, as required. The new company will touch the lives of over one billion consumers worldwide every day through its iconic portfolio of beloved brands such as AVEENO®, BAND-AID® Brand Adhesive Bandages, LISTERINE®, NEUTROGENA®, TYLENOL®, JOHNSON’S® and DR. CI:LABO®, and will continue its longstanding legacy of innovation.

Usage of the new company logo and corporate brand identity will be effective upon completion of the planned separation. More information regarding Kenvue, including the company’s board of directors and financial transaction information will be available at a later date.

The Consumer Health segment generated revenue of $14.6 billion in Full-Year 2021 and, following the planned separation, Kenvue would generate sales in over 100 countries, driven by world-class innovation capabilities and demonstrated business momentum.

In recent years, J&J has focused the Consumer Health business and advanced its innovation, enabling it to reach more consumers with products that truly make a difference in peoples’ lives, while simultaneously expanding margins and delivering healthy financial results. These actions have bolstered positions in Self Care, Skin Health and Essential Health.

To access more business news, visit NJB News Now.

Related Articles: